Science Explorer Back to mapMap
Discussion
Company · Rensselaer · United States

Pulmokine (United States)

pulmokine.netROR OpenAlex
Research works
2
▼ 83% vs 2018-21
Citations
27
14.4 per fractional work
Top-10% rate
96.0%
all institutions 10.0%
Open access
73%
world 40%
Pulmokine (United States)

Not ranked overall: Pulmokine (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Pulmokine (United States) work in?

In all years, 53% of research at Pulmokine (United States) is in Life Sciences, 42% in Health Sciences. Its largest fields are Medicine (42%), Biochemistry, Genetics and Molecular Biology (26%), Immunology and Microbiology (26%).

Life Sciences: 1 fractional works · 52.6% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 26.3% of its workImmunology and Microbiology: 0 fractional works · 26.3% of its workHealth Sciences: 1 fractional works · 42.1% of its workMedicine: 1 fractional works · 42.1% of its workPhysical Sciences: 0 fractional works · 5.3% of its workChemistry: 0 fractional works · 5.3% of its workALL ITS WORKPulmokine (UnitedStates)2fractional works, all years
Life Sciences53%Physical Sciences5%Health Sciences42%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 4 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology026.3%
    2. Immunology and Microbiology026.3%
    1. Medicine142.1%
    1. Chemistry05.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Pulmokine (United States)?

The most cited paper from Pulmokine (United States) is "Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension" (Anna Galkin, Ravikumar A. Sitapara, Bryan Clemons et al., 2022), with 73 citations. Next come "Predicting inpatient mortality for pediatric trauma patients with blunt injuries: A better alternative" (36) and "PK10453, a Nonselective Platelet‐Derived Growth Factor Receptor Inhibitor, Prevents the Progression of Pulmonary Arterial Hypertension" (29).

Most cited papers
#PaperReleasedCitations
1 Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension Anna Galkin, Ravikumar A. Sitapara, Bryan Clemons et al. · European Respiratory Journal Open access 9 Jun 2022 73
2 Predicting inpatient mortality for pediatric trauma patients with blunt injuries: A better alternative Edward L. Hannan, Louise Szypulski Farrell, Philip S. Meaker et al. · Journal of Pediatric Surgery Open access Feb 2000 36
3 PK10453, a Nonselective Platelet‐Derived Growth Factor Receptor Inhibitor, Prevents the Progression of Pulmonary Arterial Hypertension Venkatrao Medarametla, Stephen Festin, Chuluunbaatar Sugarragchaa et al. · Pulmonary Circulation Open access Mar 2014 29
4 SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling Ravikumar A. Sitapara, Chuluunbaatar Sugarragchaa, Lawrence S. Zisman · Pulmonary Circulation Open access 18 May 2021 8
5 Phosphoproteomic analysis of lung tissue from patients with pulmonary arterial hypertension Ravikumar A. Sitapara, TuKiet T. Lam, Aneta Gandjeva et al. · Pulmonary Circulation Open access Jul 2021 6
All 5 most cited papers, with filters and sorting

Which research topics does Pulmokine (United States) publish most on?

By volume in 2022-now: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD) Research and Pulmonary Hypertension Research and Treatments.

Interstitial Lung Diseas…0Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis: 0 fractional worksChronic Obstructive Pulm…0Chronic Obstructive Pulmonary Disease (COPD) Research: 0 fractional worksPulmonary Hypertension R…0Pulmonary Hypertension Research and Treatments: 0 fractional works
Pulmonary and Respiratory Medicine

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pulmonary and Respiratory Medicine 0 works
  2. 2 Chronic Obstructive Pulmonary Disease (COPD) Research Pulmonary and Respiratory Medicine 0 works
  3. 3 Pulmonary Hypertension Research and Treatments Pulmonary and Respiratory Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available73.2%not open26.8%

World: 40% of research is openly available.

How has Pulmokine (United States)'s research output changed?

Output in 2022-2025 was 83% lower than in 2018-2021.

20152020

Other research institutions in Rensselaer

All research institutions in Rensselaer

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Pulmokine (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.